Correct, it is a patent covering the combination of DCVax with a check point inhibitor but only for treatment of gliomas. Here is the pending independent claim:
1. (Previously presented) A method of treating a glioma or initiating. enhancing, or prolonging an anti-glioma response in a subject in need thereof comprising administering to the subject a therapcutic agent in combination with an agent that is a checkpoint inhibitor, wherein the therapcutic agent is a dendritic cell vaccine wherein the dendritic cell is pulsed with a glioma antigen, and wherein the agent that is a checkpoint inhibitor is an antibody specific for PD-1, PD-L1, or a fusion protein comprising PD-1 or PD-L1 for targeting PD-L1 or PD-1, or a
combination thereof.
This application will be allowed within the next month or so. After having taken a better look at the most recent rejection, the only issues needing to be taken care of was (1) submission of some “sequence listing” of nucleotide/amino acids (I’m not familiar with this as I do telecommunications type work), (2) fixing of some minor antecedent basis issues in a couple dependent claims, and (3) a filing of a terminal disclaimer to overcome a double patenting rejection. Double patenting rejections are normal and occurs when a company files multiple patent applications with similar subject matter — that is, the current application is rejected in view of another NWBO application, which can be overcome by a terminal disclaimer. A terminal disclaimer just means you’re disclaiming any extended patent term for subject matter in the current application that can find basis in the previously filed application (it is a mechanism to ensure you’re not improperly getting a longer patent term on subject matter that is contained in the previous application by filing this current application).
News 
Market Data 
Discover 
